• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

by MM360 Staff | Jul 7, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma

by MM360 Staff | Jul 4, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma

by MM360 Staff | Jul 3, 2025 | Myeloma News

Source: Pharmacy Times articles The treatment becomes the first approved BCMAxCD3 bispecific antibody with the potential to achieve biweekly or monthly dosing in patients with relapsed/refractory multiple myeloma. Read More

Comprehensive machine learning analysis of PANoptosis signatures in multiple myeloma identifies prognostic and immunotherapy biomarkers

by MM360 Staff | Jul 2, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials

by MM360 Staff | Jul 2, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Spatial and single cell mapping of castleman disease reveals key stromal cell types and cytokine pathways

by MM360 Staff | Jul 1, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases
  • Carvykti label updated to include survival benefit data in myeloma
  • Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
  • Inflammatory markers from routine blood tests predict survival in multiple myeloma: a Systematic Review and meta-analysis
  • FDA approves ziftomenib to treat some relapsed leukemia patients
  • (no title)
  • The challenge of non-transplant eligible, newly diagnosed multiple myeloma
  • Camera pill to find pancreatic cancer seeks breakthrough status
  • Camera pill to find pancreatic cancer seeks breakthrough status
  • Tinostamustine named orphan drug for treating malignant gliomas
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT